Intraoperative Intraperitoneal Chemoperfusion to Treat Peritoneal Minimal Residual Disease in Stage III Ovarian Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Clinical Trials Related to Primary Peritoneal Cancer
Related studies linked through entity extraction aliases.
Study of Safety & Biological Activity of IP IMNN-001 (also Known As GEN-1) with Neoadjuvant Chemo in Ovarian Cancer
- Status
- COMPLETED
- Phase
- PHASE1
Autologous OC-L Vaccine and Ovarian Cancer
- Status
- TERMINATED
- Phase
- PHASE1
p53 Gene in Treatment of Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer
- Status
- UNKNOWN
- Phase
- PHASE2
Flaxseed as Maintenance Therapy for Ovarian Cancer Patients in Remission
- Status
- COMPLETED
- Phase
- PHASE1
Phase 2 Trial of Regorafenib in Patients With Recurrent Ovarian, Primary Peritoneal and Fallopian Tube Cancer
- Status
- TERMINATED
- Phase
- PHASE2
Dose-Escalation Study of Intraperitoneal (IP) Cisplatin, IV/IP Paclitaxel, IV Bevacizumab, and Oral Olaparib for Newly Diagnosed Ovarian, Primary Peritoneal, and Fallopian Tube Cancer
- Status
- COMPLETED
- Phase
- PHASE1
GANNET53: Ganetespib in Metastatic, p53-mutant, Platinum-resistant Ovarian Cancer
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Pilot Trial of BMN 673, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Deleterious BRCA Mutations
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
PankoMab-GEX™ Versus Placebo as Maintenance Therapy in Advanced Ovarian Cancer
- Status
- COMPLETED
- Phase
- PHASE2
"Re-Stimulated" TILs and IL-2 Therapy for Platinum Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Tai-chi / Qi-gong in Patients With Patients With Gynecological Malignancies
- Status
- WITHDRAWN
- Phase
- PHASE1/PHASE2
Vitamin D for Women at Increased Risk of Developing Ovarian, Fallopian, or Primary Peritoneal Cancer
- Status
- TERMINATED
- Phase
- NA
VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
- Status
- COMPLETED
- Phase
- PHASE2
A Study LY2228820 for Recurrent Ovarian Cancer
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
CRLX101 in Combination With Bevacizumab for Recurrent Ovarian/Tubal/Peritoneal Cancer
- Status
- COMPLETED
- Phase
- PHASE2
A Phase IIclinical Trial of Carboplatin and Paclitaxel or Carboplatin and Gemcitabine in Platinum-sensitive, Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer
- Status
- UNKNOWN
- Phase
- PHASE2
Study of ABT-767 in Subjects With Breast Cancer 1 and Breast Cancer 2 (BRCA 1 and BRCA 2) Mutations and Solid Tumors or High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
- Status
- COMPLETED
- Phase
- PHASE1
A Clinical Trial of Autologous Oxidized Tumor Cell Lysate Vaccine For Recurrent Ovarian, Fallopian Tube or Primary Peritoneal Cancer
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Autologous T-Cells Combined With Autologous OC-DC Vaccine in Ovarian Cancer
- Status
- TERMINATED
- Phase
- PHASE1